Blair William & Co. IL Reduces Stock Position in Intuitive Surgical, Inc. $ISRG

Blair William & Co. IL reduced its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 458,006 shares of the medical equipment provider’s stock after selling 8,017 shares during the period. Blair William & Co. IL owned approximately 0.13% of Intuitive Surgical worth $204,834,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Norges Bank bought a new position in shares of Intuitive Surgical in the 2nd quarter worth approximately $2,569,260,000. Rakuten Investment Management Inc. bought a new position in Intuitive Surgical in the third quarter worth approximately $388,436,000. Vanguard Group Inc. boosted its stake in shares of Intuitive Surgical by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock worth $18,115,025,000 after acquiring an additional 670,302 shares during the last quarter. Victory Capital Management Inc. grew its position in shares of Intuitive Surgical by 41.3% during the 3rd quarter. Victory Capital Management Inc. now owns 1,941,310 shares of the medical equipment provider’s stock valued at $868,212,000 after acquiring an additional 567,483 shares during the period. Finally, Canada Pension Plan Investment Board increased its stake in shares of Intuitive Surgical by 27.1% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,089,293 shares of the medical equipment provider’s stock worth $591,933,000 after purchasing an additional 231,980 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Insiders Place Their Bets

In related news, Director Gary S. Guthart sold 2,800 shares of the business’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $531.52, for a total value of $1,488,256.00. Following the sale, the director directly owned 15,720 shares in the company, valued at approximately $8,355,494.40. The trade was a 15.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 648 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $495.20, for a total value of $320,889.60. Following the completion of the sale, the senior vice president directly owned 2,906 shares in the company, valued at approximately $1,439,051.20. The trade was a 18.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 37,261 shares of company stock worth $19,690,721. 0.70% of the stock is owned by corporate insiders.

Intuitive Surgical Price Performance

Shares of ISRG opened at $490.16 on Friday. The firm has a market cap of $174.07 billion, a P/E ratio of 62.12, a price-to-earnings-growth ratio of 3.83 and a beta of 1.66. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $603.88. The company has a 50 day simple moving average of $521.64 and a two-hundred day simple moving average of $512.05.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, topping the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The firm had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the previous year, the firm earned $2.21 earnings per share. The company’s quarterly revenue was up 18.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Sanford C. Bernstein boosted their price target on Intuitive Surgical from $740.00 to $750.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Truist Financial boosted their price objective on Intuitive Surgical from $620.00 to $650.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings restated a “hold (c+)” rating on shares of Intuitive Surgical in a research note on Monday, December 29th. Robert W. Baird dropped their price target on shares of Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, BTIG Research restated a “buy” rating and set a $616.00 price objective on shares of Intuitive Surgical in a research report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $615.86.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.